225 related articles for article (PubMed ID: 32784322)
1. Successful Combination of Neuraxial and Regional Anesthesia in a Child With Advanced Spinal Muscular Atrophy Type 1 Receiving Maintenance Nusinersen Therapy: A Case Report.
Brown AF; Einhorn LM
A A Pract; 2020 Apr; 14(6):e01206. PubMed ID: 32784322
[TBL] [Abstract][Full Text] [Related]
2. Cervical puncture to deliver nusinersen in patients with spinal muscular atrophy.
Veerapandiyan A; Pal R; D'Ambrosio S; Young I; Eichinger K; Collins E; Westesson PL; Kwon J; Ciafaloni E
Neurology; 2018 Aug; 91(7):e620-e624. PubMed ID: 30006410
[TBL] [Abstract][Full Text] [Related]
3. Anesthetic management of pediatric patients undergoing intrathecal nusinersen administration for treatment of spinal muscular atrophy: A single-center experience.
Brollier LD; Matuszczak M; Marri T; Carbajal JG; Moorman AT; Sorial EM; Jain R
Paediatr Anaesth; 2021 Feb; 31(2):160-166. PubMed ID: 32623818
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive institutional overview of intrathecal nusinersen injections for spinal muscular atrophy.
Mousa MA; Aria DJ; Schaefer CM; Kaye RD; Abruzzo TA; Bernes SM; Willard SD; Riemann MC; Towbin RB
Pediatr Radiol; 2018 Nov; 48(12):1797-1805. PubMed ID: 30022258
[TBL] [Abstract][Full Text] [Related]
5. Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database Analysis.
Gauthier-Loiselle M; Cloutier M; Toro W; Patel A; Shi S; Davidson M; Bischof M; LaMarca N; Dabbous O
Adv Ther; 2021 Dec; 38(12):5809-5828. PubMed ID: 34713391
[TBL] [Abstract][Full Text] [Related]
6. Nusinersen: First Global Approval.
Hoy SM
Drugs; 2017 Mar; 77(4):473-479. PubMed ID: 28229309
[TBL] [Abstract][Full Text] [Related]
7. Nusinersen Administration Via an Intrathecal Port in a 16-Year-Old Spinal Muscular Atrophy Patient with Profound Scoliosis.
Flotats-Bastardas M; Linsler S; Zemlin M; Meyer S
Pediatr Neurosurg; 2020; 55(1):54-57. PubMed ID: 31722365
[TBL] [Abstract][Full Text] [Related]
8. Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps.
Gidaro T; Servais L
Dev Med Child Neurol; 2019 Jan; 61(1):19-24. PubMed ID: 30221755
[TBL] [Abstract][Full Text] [Related]
9. Nusinersen for the treatment of spinal muscular atrophy.
Chiriboga CA
Expert Rev Neurother; 2017 Oct; 17(10):955-962. PubMed ID: 28884620
[TBL] [Abstract][Full Text] [Related]
10. Nusinersen: A Treatment for Spinal Muscular Atrophy.
Claborn MK; Stevens DL; Walker CK; Gildon BL
Ann Pharmacother; 2019 Jan; 53(1):61-69. PubMed ID: 30008228
[TBL] [Abstract][Full Text] [Related]
11. Inflammatory markers in cerebrospinal fluid of paediatric spinal muscular atrophy patients receiving nusinersen treatment.
Scheijmans FEV; Cuppen I; Zwartkruis MM; Signoria I; van Ekris C; Asselman F; Wadman RI; Knol EF; van der Pol WL; Groen EJN
Eur J Paediatr Neurol; 2023 Jan; 42():34-41. PubMed ID: 36525882
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of nusinersen in type 1, 2 and 3 spinal muscular atrophy: Real world data from Hungarian patients.
Szabó L; Gergely A; Jakus R; Fogarasi A; Grosz Z; Molnár MJ; Andor I; Schulcz O; Goschler Á; Medveczky E; Czövek D; Herczegfalvi Á
Eur J Paediatr Neurol; 2020 Jul; 27():37-42. PubMed ID: 32456992
[TBL] [Abstract][Full Text] [Related]
13. Nusinersen treatment of Spinal Muscular Atrophy Type 1 - results of expanded access programme in Poland.
Modrzejewska S; Kotulska K; Kopyta I; Grędowska E; Emich-Widera E; Tomaszek K; Paprocka J; Chmielewski D; Pilch J; Pietruszewski J; Lemska A; Zawadzka M; Mazurkiewicz-Bełdzińska M
Neurol Neurochir Pol; 2021; 55(3):289-294. PubMed ID: 33565602
[TBL] [Abstract][Full Text] [Related]
14. Current evidence for treatment with nusinersen for spinal muscular atrophy: a systematic review.
Meylemans A; De Bleecker J
Acta Neurol Belg; 2019 Dec; 119(4):523-533. PubMed ID: 31388901
[TBL] [Abstract][Full Text] [Related]
15. Nusinersen as a Therapeutic Agent for Spinal Muscular Atrophy.
Li Q
Yonsei Med J; 2020 Apr; 61(4):273-283. PubMed ID: 32233169
[TBL] [Abstract][Full Text] [Related]
16. Effect of Discontinuation of Nusinersen Treatment in Long-Standing SMA3.
Hiebeler M; Abicht A; Reilich P; Walter MC
J Neuromuscul Dis; 2021; 8(4):537-542. PubMed ID: 33682724
[TBL] [Abstract][Full Text] [Related]
17. Real-World Data from Nusinersen Treatment for Patients with Later-Onset Spinal Muscular Atrophy: A Single Center Experience.
Mendonça RH; Polido GJ; Matsui C; Silva AMS; Solla DJF; Reed UC; Zanoteli E
J Neuromuscul Dis; 2021; 8(1):101-108. PubMed ID: 33074187
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacological and clinical profile of spinal muscular atrophy (SMA) therapeutic drug nusinersen (Spinraza
Ohmura T; Saeki S; Ogiwara K; Tobita K; Ling Y; Torii S
Nihon Yakurigaku Zasshi; 2018; 152(3):147-159. PubMed ID: 30185733
[TBL] [Abstract][Full Text] [Related]
19. Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells.
Pagliarini V; Guerra M; Di Rosa V; Compagnucci C; Sette C
J Neurochem; 2020 Apr; 153(2):264-275. PubMed ID: 31811660
[TBL] [Abstract][Full Text] [Related]
20. Intrathecal administration of nusinersen in adolescent and adult SMA type 2 and 3 patients.
Wurster CD; Winter B; Wollinsky K; Ludolph AC; Uzelac Z; Witzel S; Schocke M; Schneider R; Kocak T
J Neurol; 2019 Jan; 266(1):183-194. PubMed ID: 30460449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]